- Odyssey Health is a medical company specializing in the development of unique, life-saving medical products that provide solutions to unmet clinical needs, one of which is concussion, which currently does not have an FDA-approved drug
- The company has developed the PRV-002 drug candidate, which is designed to be administered intranasally where pre-clinical results have shown to be effective in treating a concussion within 30 minutes of administration
- Through its drug candidate, Odyssey hopes to reduce the risks and potential for long-term consequences associated with concussions
Up until Olympic gold medalist Katie Weatherston was forced into retirement following a series of mild traumatic brain injuries (“mTBIs”) or concussions, she and her professional career were blossoming. As a member of the Canadian national team, Katie won a gold medal in the ice hockey tournament at the 2006 Olympic Games in Turin, Italy. In 2007, she again was a gold medalist at the 2007 IIHF Ice Hockey Women’s World Championship held in Canada; a year later, at the IIHF Championship tournament held in China, she would go on to win a silver medal (https://ibn.fm/LVU6f).
Indeed, Weatherston’s career comprised moments most athletes only dream of; but during an interview published in 2013 on CTV Ottawa Morning Live’s YouTube channel (https://ibn.fm/6AVQg), she asked whether it was worth the life-long consequences she could have, to which she ruefully answered, “Probably not.”
The figurative beginning of the end, at least career-wise, started in 2005 when she flew over the handlebars during a bike race with her team. Then in 2006, she was hit from the back and went head first into the boards at a training camp; the team doctor cleared her after assessing her for a concussion, allowing her to get back into the game. But she suffered two more blows to the head. Within the next few days, Katie developed concussion symptoms and was eventually confirmed to have sustained a concussion, forcing her out of the game for several months. Fortunately, she eventually got back to doing what she loved, albeit for a short period, until a minor fall gave her whiplash in 2008 (https://ibn.fm/MQnOm).
For the 16 years since the 2006 series of injuries, Katie told CBC in an interview, she has struggled with daily headaches, chronic exhaustion, and the sensation of her ears popping. And to cope, she has had to seek medical care in the form of, among others, physiotherapy and chiropractor appointments, which require her to fork out CA$30,000 to CA$40,000 a year. Katie had been left with prolonged or persistent post-concussion syndrome (“PPCS”) (https://ibn.fm/Caq8o).
Although concussion holds the potential to upend life, causing lingering symptoms that complicate everyday activities, it currently does not have an FDA-approved treatment. This is despite the fact that between 1.6-3.8 million concussions occur in the United States every year (https://ibn.fm/N0HT1), with 10-20% of these cases likely to lead to PPCS (https://ibn.fm/cSgTP).
In recognizing this gap, Odyssey Health (OTC: ODYY), a medical company developing unique, life-saving medical products that provide solutions to unmet clinical needs, embarked on the development and evaluation of PRV-002, a novel compound for the treatment of concussion. Through in-vivo animal testing, PRV-002 has been shown to have anti-inflammatory, antioxidant, and antiedematous properties that ensure it eliminates the immediate consequences of a concussion, namely swelling, oxidative stress, and inflammation in the brain while restoring proper blood flow. Additionally, animal models of concussion have demonstrated that PRV-002 reduces behavioral pathology linked to mTBI symptoms such as motor/sensory performance, anxiety, and memory impairment.
Odyssey recently completed its registered Phase I trial, which was segmented into Single Ascending Dosing (“SAD”) and Multiple Ascending Dosing (“MAD”) portions, both of which evidenced that PRV-002 is safe and well-tolerated when administered to healthy subjects (https://ibn.fm/qFt73). Next, the company is planning a Phase II trial that will evaluate the efficacy of the drug candidate in concussed patients. The study will initially be domiciled in select military sites where personnel are prone to sustaining concussions during training.
Designed to be delivered via the Odyssey’s novel intranasal drug delivery device, the drug candidate is meant to be administered within minutes of a concussion episode, allowing it to reverse the effects of the blow or jolt to the head. This immediate action is attributable to the intranasal delivery, which deposits the dry powder to the upper chamber of the nasal cavity for onward travel to the brain via the cranial nerve, and the drug’s lipophilic properties that enable it to cross the blood-brain barrier.
Once approved, PRV-002 is poised to potentially reduce the risks posed by concussions, which have impacted the lives of many professional athletes, some of whom, like Katie Weatherston, have been forced into retirement and still have lingering symptoms such as balance problems, difficulty focusing their gaze, dizziness, depression, and chronic exhaustion (https://ibn.fm/aRX4f).
For more information, visit the company’s website at www.OdysseyHealthInc.com.
NOTE TO INVESTORS: The latest news and updates relating to ODYY are available in the company’s newsroom at https://ibn.fm/ODYY
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. It is part of our mission statement to help the investment community discover emerging companies that offer excellent growth potential. We offer several ways for investors to learn more about investing in these companies as well as find and evaluate them.
QualityStocks (QS)
Scottsdale, Arizona
www.QualityStocks.com
480.374.1336 Office
Editor@QualityStocks.com
Please see full terms of use and disclaimers on the QualityStocks website applicable to all content provided by QS, wherever published or re-republished: http://www.qualitystocks.net/disclaimer.php
No comments:
Post a Comment